A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples